FarmaKology Newsletter - Issue #57
Diagnosia is a new kind of medical software company and we believe that it's time to truly support physicians in the their daily clinical decisions, at the point of care, with most intuitive, simplest interfaces.Diagnosia is Austria's most used doctor app and and fully integrated in over 65 hospitals across Austria, Germany and Switzerland.We genuinely believe in making medicine simple through software.
Isofol Medical , has announced today that the company has further strengthened its position in the second largest market for treatment of mCRC by obtaining two new patent grants for arfolitixorin in Japan. One relates to the preparation process of the drug for injection and one relates to the dosage regimens, including those applied in the ongoing global Phase III study AGENT. Together with the already granted Active Substance Patent (API), these two patents will ensure a strong and extended patent protection for the important future Japanese market until 2038.
WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate
WPD Pharmaceuticals Inc., a clinical stage pharmaceutical company, is excited to announce that a recently published study confirms the high therapeutic potential of IL-13RA2- and EphA2 receptor-targeted cytotoxins in the WPD101 drug candidate. The study found the combination of these cytotoxins as a highly effective anticancer therapy in dogs with spontaneous intracranial gliomas.
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
Gilead Sciences, Inc. today announced an agreement with Jounce Therapeutics, Inc. , a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.
Novavax, Inc. , a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.
Research & Study
Listen to Identifying Barriers To And Developing Opportunities For Rotavirus Vaccination and 119 more episodes by PeerVoice Clinical Pharmacology Audio, free! No signup or install needed. Identifying Barriers to and Developing Opportunities for Rotavirus Vaccination. Weighing Evidence and Perspectives on JAK Inhibitors in Psoriatic Arthritis: Can We Do More for Patients?.